THEMIS MEDICARE LTD. SHARE PRICE [LIVE]

BSE: INE083B01016   NSE: THEMISMED   SECTOR: Pharma

OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
809.80
Change:
BSE
804.95
Change:
NSE
BSE Click here to view BSE data
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality
Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
Sector
Sensex
Name Mar 21 Dec 20

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in THEMIS MEDICARE LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

THEMISMED News

Frequently Asked Questions

What is the Share price of THEMIS MEDICARE LTD. (THEMISMED)?

THEMIS MEDICARE LTD. (THEMISMED) share price as of August 5, 2022, on NSE is Rs 809.80 (NSE) and Rs 804.95 (BSE) on BSE.

Can I buy THEMIS MEDICARE LTD. (THEMISMED) shares?

Yes, You can buy THEMIS MEDICARE LTD. (THEMISMED) shares by opening a Demat account with Angel One.

How do I buy THEMIS MEDICARE LTD. (THEMISMED) from Angel One?

THEMIS MEDICARE LTD. (THEMISMED) share can be brought through the following modes:
  1. Direct investment: You can buy THEMIS MEDICARE LTD. (THEMISMED) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to THEMIS MEDICARE LTD. (THEMISMED) shares.

In which sector do THEMIS MEDICARE LTD. (THEMISMED) belong?

THEMIS MEDICARE LTD. (THEMISMED) belongs to Pharma.

About THEMISMED

Today's live share price for THEMIS MEDICARE LTD. is NSE: ₹ 809.80, BSE: ₹ 804.95 with a current market capitalization of .

Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital. Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments. Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary. The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products through the collborators throughout the Russian Federation for trade,tenders and govt.supplies.

Read more